Patients with type 2 diabetes mellitus (T2DM) 
Introduction
The incidences of both type 1 and type 2 diabetes are rising. The global pandemic principally involves the T2DM which is associated with greater longevity, obesity, unsatisfactory diet, sedentary lifestyle and increasing urbanization1. An estimated 366 million people worldwide had diabetes in 2011 and this number is projected to reach 552 million in 2030 2 . T2DM remains a leading cause of cardiovascular (CV) disorders, blindness, end-stage renal failure, amputations, and hospitalizations. It is also associated with increased risk of cancer, cognitive decline, chronic liver disease, and other disabling or deadly conditions 3 . Patients with T2DM are usually treated with pharmacologic agents in combination with lifestyle modification. The large number of new classes of agents developed after 1995 (initially the introduction of meglitinides, the alfaglucosidase inhibitors and the thiazolidinediones) reflects the increase in our understanding of the multiple targets for improving hyperglycemia. The further development of antidiabetic agents, such as insulin analogs and incretin-based therapies (DPP-4 inhibitors and GLP-1 analogs), has led to treatment strategies that enable many patients with T2DM to achieve target HbA1c levels ( 7.0%) 4 . Other agents which have been included in the pharmacotherapy T2DM are amylin analog (pramlintide), bile acid sequestrants (colesevelam) and D2 dopamine receptor agonists (bromocriptine) 5 . Effective management strategies are of obvious importance. But glycemic management in T2DM has become increasingly complex with a widening array of pharmacological agents now available. Pharmacologic treatment of patients with T2DM is limited not only by the effectiveness of the agents but also by their adverse effects. Although numerous reviews on the management of T2DM have been published in the past and recent years, practitioners are often left without a clear pathway of therapy to follow. This review article discusses the current pharmacological agents used, their latest successes, merits, demerits and limitations in the treatment of patients with T2DM. This article also reviews the different updated guidelines and algorithms provided by expert committees of ADA/EASD, IDF, American Association of Clinical Endocrinologists (AACE), and American College of Physicians (ACP).
Overview of pathophysiology of type 2 diabetes
T2DM is a disease that is heterogeneous in both pathogenesis and in clinical manifestation-a point to be considered when determining the optimal therapeutic strategy for individual patients. Insulin resistance in muscle & liver and beta-cell failure represent the core pathophysiologic defects in type 2 diabetes and are well established early in the natural history of the disease, but T2DM does not occur in the absence of progressive beta cell failure. In addition to the muscle, liver and beta-cell, the alfa-cell (hyperglucagonemia), gastrointestinal tract (incretin deficiency), fat cell (accelerated lipolysis), kidney (increased glucose reabsorption), and brain (insulin resistance) all play important roles in the development of T2DM (Figure 1 ) 6 . Collectively, these eight players comprise the ominous octet and dictate that multiple drugs used in combination will be required to correct the multiple pathophysiological defects, and that therapy must be started early to prevent/slow the progressive beta-cell failure. In liver, the insulin resistance is manifested by an overproduction of glucose during the basal state. So in the fasting state, hyperglycemia is directly related to increased hepatic glucose production. In the postprandial state, hyperglycemia is related to defective insulin stimulation of glucose disposal in target tissues, mainly skeletal muscle with impaired glucose uptake following ingestion of a carbohydrate meal 6 . Amylin is a natural hormone produced by the beta-cell of the pancreas and is co-secreted with insulin in response to a glucose load. It inhibits glucagon production, slows gastric emptying, and also stimulates satiety. In T2DM, there is impairment of amylin secretion by the pancreatic betacells. More recently abnormalities in the incretin system (GLP-1) have been recognized in T2DM 7 . GLP-1 is a naturally occurring peptide produced by the l-cells of the small intestine. In addition to stimulating glucose dependant insulin secretion, GLP-1 suppresses glucagon and slows gastric emptying, and also acts on the hypothalamus to induce satiety. 
Antidiabetic drugs
Currently, 11 unique classes of drugs are available for the treatment of patients with T2DM in most countries, and are approved by the Food and Drug Administration < (FDA) for their use in US 8 . The glycemic control in T2DM is achieved with some agents that predominantly lower the fasting plasma glucose level (metformin, sulfonylureas and basal insulins); with others that primarily lower postprandial plasma glucose excursions {meglitinides, alfa-glucosidase inhibitors (AGIs), pramlintide, exenatide and prandial insulins); and with still others that do both {thiazolidinediones (TZDs), DPP-4 inhibitors, liraglutide and premixed insulins) 4 .
The glucose-lowering effectiveness of noninsulin pharmacological agents is said to be high for metformin, sulfonylureas (SUs), TZDs, and GLP-1 analogs, and generally lower for meglitinides, AGIs, DPP-4 inhibitors, colesevelam, and bromocriptine 9,10,11 . The problems of unwanted hypoglycemia, weight gain, and beta cell failure are limiting the use of SUs after availability of modern drugs. The glycemic benefits of SUs are nearly fully realized at half-maximal doses, and higher doses should generally be avoided 13 .
Oral agents

c. MEGLITINIDES:
The meglitinides have short duration of action, lowers postprandial glucose level and needs frequent dosing. As such these drugs are indicated for postprandial hyperglycemia. Of the two glinides, nateglinide is somewhat less effective in lowering HbA1c than repaglinide when used as monotherapy or in combination therapy 13 . These drugs are associated with hypoglycemia and weight gain. Meglitinides can be used in liver dysfunction3. Repaglinide and nateglinide do not undergo significant renal clearance but caution is imperative at more severe degrees of renal dysfunction3.
d. THIAZOLIDINEDIONES (TZDs):
The drugs in this class include pioglitazone and rosiglitazone. TZDs are most likely to be effective in patients with pronounced insulin resistance (e.g. in abdominal obesity). Other advantages are-no hypoglycemia, , HDL cholesterol and Triglycerides. Pioglitazone is not eliminated renally, and therefore there are no restrictions for use in chronic kidney disease (CKD) 3 . There is preliminary evidence that patients with fatty liver may benefit from treatment with pioglitazone 3 . The most common adverse effects with TZDs are weight gain and fluid retention with peripheral edema. TZDs must be avoided in patients with cardiac failure. TZDs should not be used if ALT is 2.5-3 times normal upper limits 3, 15 . In addition both the drugs have increased risk of fracture particularly in women. TZDs increase peripheral (subcutaneous) adipose tissue mass with some reduction in visceral fat 13 . In July 2007 a study published in NEJM shows 40% increase risk of CV events and death among users of rosiglitazone 18 . The European Medicines Agency (EMA) is phasing out the use of rosiglitazone. In September 2010 FDA significantly restricts access to rosiglitazone. FDA decision: rosiglitazone will be available to new patients only if they are unable to achieve glucose control on other medications and are unable to take pioglitazone, the only other drug in this class 19 . Current users of rosiglitazone who are benefiting from the drug will be able to continue using the medication if they choose to do so. Pioglitazone has recently been associated with a possible increased risk of bladder cancer and has drawn attention 20 . In June 2011-France and Germany suspended use of pioglitazone. FDA & EMA is recommending that T2DM patients with current bladder cancer, a history of the disease, or uninvestigated macroscopic hematuria, should not be prescribed pioglitazone.
e. ALPHA-GLUCOSIDASE INHIBITORS (AGIs):
Acarbose, miglitol and voglibose are the drugs in this group. The AGIs are effective in lowering postprandial hyperglycemia modestly without causing hypoglycemia but may have gastrointestinal side effects. There may be slight reduction in the body weight and serum triglycerides. They are less effective in lowering glycemia than metformin or the sulfonylureas when used as monotherapy. The AGIs should not be used with renal dysfunction. Figure 2 ) to help guide health care providers in choosing the most appropriate interventions for their patients with T2DM 13 .
Highlights include intervention at the time of diagnosis with metformin in combination with lifestyle changes and continuing timely augmentation of therapy with additional agents from a different class (including early initiation of insulin therapy) as a means of achieving and maintaining recommended levels of glycemic control (i.e. HbA1c <7% for most patients). In the setting of severely uncontrolled diabetes, defined as fasting plasma glucose levels >13.9 mmol/l (250 mg/dl), random glucose levels consistently above 16.7 mmol/l (300 mg/dl), HbA1c above 10%, or the presence of ketonuria, or as symptomatic diabetes with polyuria, polydipsia and weight loss, insulin therapy at the outset in combination with lifestyle intervention is the treatment of choice 13 . After symptoms are relieved and glucose levels decreased, oral agents can often be added and it may be possible to withdraw insulin, if preferred 13 . Figure 3 ). The previous recommendation for all patients on glycemic targets HbA1c of <7% % has also been elaborately modified. Importance has been provided to individualize treatment targets. For example, the blood sugar goal for a young, otherwise healthy patient should be lower (an HbA1c of 6-6.5 percent) than that of an older patient with other health problems (HbA1c 7.5-8 percent) 3 . At diagnosis, highly motivated patients with HbA1c already near target (e.g. <7.5%) could be given the opportunity to engage in lifestyle change for a period of 3-6 months before embarking on pharmacotherapy. Those with moderate hyperglycemia or in whom lifestyle changes are anticipated to be unsuccessful should be promptly started on an antihyperglycemic agent (usually metformin) at diagnosis, which can later be modified or possibly discontinued if lifestyle changes are successful. If a patient presents with significant hyperglycemic symptoms and/or has dramatically elevated plasma glucose concentrations (e.g., >16.7-19.4 mmol/L [>300-350 mg/dL]) or HbA1c (e.g., 10.0-12.0%), insulin therapy should be strongly considered from the outset. In order to minimize the risk of diabetes related complications, the goal of therapy is to achieve a HbA1c of 6.5% or less, with recognition of the need for individualization to minimize the risks of hypoglycemia. The AACE/ACE algorithm includes lifestyle modification as the foundation of antihyperglycemic therapy, while pharmacologic recommendations are stratified by baseline HbA1c. Upon diagnosis, monotherapy is recommended for patients with HbA1c <7.5%, dual therapy for patients with HbA1c 7.6%-9%, and insulin for patients with HbA1c >9%. If the treatment goal of <6.5% is not met within 2 to 3 months, AACE recommends intensifying therapy by adding another agent from a different class. Metformin is designated as the preferred first-line choice in both monotherapy and dual therapy regimens.
d. In April 2011 the AACE released new medical guidelines for developing comprehensive care plan for management of diabetes mellitus 31 . The guidelines recommend a target HbA1c level of 6.5% or less in general, but recognize the need for individual treatment plans and emphasize personalized glycemic goals. Blood glucose targets should be individualized and take into account life expectancy, duration of disease, presence or absence of other complications, cardiovascular risk factors, comorbid conditions and psychological, social, and economic status as well as risk for development of and consequences from severe hypoglycemia.
e. IDF treatment algorithm recommends glycemic target value for HbA1c of <7% ( Figure 5 ) 32 . IDF document released in 2011 concentrates on the role of postprandial hyperglycemia and has advocated the target for postmeal glucose 9.0 mmol/l (160 mg/dl) as long as hypoglycemia is avoided 33 . The section presents a description of the pharmacologic agents preferentially lowering postmeal plasma glucose taking into consideration locally available therapies and resources. This approach also complements the IDF treatment algorithm for people with type 2 diabetes ( Figure 5 ). 
Antidiabetic drugs in pregnancy & lactation
Regular or rapid-acting insulin analogs are the preferred treatment for postprandial hyperglycemia in pregnant women. Basal insulin needs can be provided by using long-acting insulin (e.g. NPH; FDA pregnancy category B) 31 . Among the oral antidiabetic agents, metformin and acarbose are classified as category B and all others as category C. Although insulin is the preferred treatment approach, metformin and glibenclamide have been shown to be effective alternatives and without adverse effects in some women 31 . However potential risks and benefits of oral antidiabetic agents in must be carefully weighed, recognizing that data are insufficient to establish the safety of these agents in pregnancy 5 . Insulin requirements drop immediately after delivery, and a dose adjustment will be needed to allow for the eating patterns of the breastfeeding mother. Metformin and possibly glibenclamide may be used 34 .
The medications should be reviewed taking into consideration the potential risks associated with any transfer into the milk. The baby should, however, be monitored for signs of hypoglycemia. The very limited amounts of metformin observed in breast milk are highly unlikely to lead to substantial exposure in the breastfed baby. Metformin can be considered a safe medication for the treatment of T2DM in a breastfeeding mother 35 .
Discussion
A large amount of information is available on the efficacy of the various antidiabetic regimens used to achieve long-term glycemic control in patients with T2DM. The results from the UK Prospective Diabetes Study (UKPDS) 36 and the A Diabetes Outcome Progression Trial (ADOPT) 17 showed quite clearly that a patient's response to any one specific antidiabetic agent decreases with time. The authors of these studies suggested that complex regimens with multiple agents that have different mechanisms of action will be required to maintain target HbA1c goals in the long term 17, 36 . Selection of the individual agents should be made on the basis of their glucose-lowering effectiveness, and overall other characteristics including the individual patient.
The primary goal of chronic treatment of T2DM is to reduce the incidence of microvascular and macrovascular complications by adequate and chronic glycemic control. The mean level of HbA1c is a measure of chronic glycemic control. The ADA's "Standards of Medical Care in Diabetes" in 2011 recommends lowering HbA1c to <7.0% in most patients to reduce the incidence of microvascular disease 37 ; ideally, fasting and premeal glucose should be maintained at <7.2 mmol/L (<130 mg/dL) and the postprandial glucose at <10 mmol/L (<180 mg/dL). In June 2012, ADA/EASD have developed and promoted a new, patient-centered guideline for glycemic management in T2DM. They emphasized that all treatment decisions, where possible, should be made with the patient, focusing on his/her preferences, needs, and values. Importance has been provided to individualize treatment targets. Their recommendation were that more stringent HbA1c targets (e.g. 6.0-6.5%) might be considered in selected patients (with short disease duration, long life expectancy, no significant CVD) if this can be achieved without significant hypoglycemia or other adverse effects of treatment 3, 5 . Conversely, less stringent HbA1c goals-e.g., 7. 13 . But in June 2012, they advocates lifestyle changes for newly diagnosed patients with T2DM who are highly motivated with HbA1c already near target (e.g. <7.5%) 3 .
Therefore it is evident that lifestyle changes remain the foundation of treatment program of T2DM. Metformin is considered as initial drug for the treatment of T2DM by most of the updated guidelines. It is cheaper than most other pharmacologic agents, has better effectiveness, and is associated with fewer adverse effects. Patient having moderate hyperglycemia or in whom lifestyle changes are anticipated to be unsuccessful should be promptly started with oral antidiabetic agent preferably with metformin at diagnosis, which can later be modified or possibly discontinued if lifestyle changes are successful 3 . If glycemic targets are not achieved by monotherapy (metformin) alone then one can proceed to dual therapy, and further advancing to triple therapy by combining drugs from different classes having different mechanism of actions which may include basal insulin. Choice is based on patient and drug characteristics like susceptibilities to side effects, potential for weight gain & hypoglycemia and comorbidities. Patients with T2DM requiring insulin therapy can be successfully treated with basal insulin alone. It is usually prescribed in conjunction with one to two noninsulin agents. Consideration should be given to the addition of prandial or mealtime insulin coverage when significant postprandial glucose excursions occur. Progression from basal insulin to a twice-daily premixed insulin-could also be considered. Importantly, most patients with T2DM maintain some endogenous insulin secretion even in late stages of disease. Accordingly, the more complex and intensive strategies of type 1 diabetes are not typically necessary 3 .
Medical therapy for patients with T2DM has improved considerably during the past decade. A substantial percentage of patients with T2DM can achieve target glycemic control with minimal adverse effects from their medical treatment. Obviously, the choice of glycemic goals and the medications used to achieve them must be individualized for each patient, balancing the potential for lowering HbA1c and anticipated longterm benefit with specific safety issues, as well as other characteristics of regimens, including side effects, tolerability, ease of use, long-term adherence, expense, and the nonglycemic effects of the medications.
